Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

In this study, implantable vascularized engineered thrombi using autologous whole blood improved skin wound healing in rats by promoting robust microcapillary networks and accelerating healing processes.

The conclusion suggests a new treatment for infantile hemangiomas and a potential target for hair loss treatment.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

This review explores the mechanisms and clinical trials of topical minoxidil for hair loss but presents no new clinical findings, emphasizing the need for better understanding of hair loss etiology for effective treatments.

This study concluded that topical minoxidil could effectively accelerate nail growth in both healthy individuals and those with nail disorders, though the regimen might differ across these groups.

This article reviews low-level light therapy for various types of hair loss and reports no new clinical results; the authors note its safety and advantages but lack data on individual treatment response.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study optimized conditions for quantifying minoxidil using high-performance liquid chromatography, establishing specific parameters for mobile phase, flow rate, column temperature, and retention time.

In this placebo-controlled study, finasteride significantly improved symptoms, reduced prostate size, and increased urine flow rate in patients with moderately symptomatic BPH over two years.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.

This study found that individuals with ectodermal dysplasias often have a reduced secretion rate of submandibular saliva and altered protein concentrations, suggesting routine salivary tests may be beneficial in this population.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

In this study, forming inclusion complexes of Finasteride and poly (ethylene glycol) resulted in significantly improved solubility and dissolution rates, suggesting a promising new solid form for enhanced drug release.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This study validated a new RP-HPLC method for accurately determining doxazosin mesylate and finasteride in bulk powders and capsule formulations.

This study developed and validated a precise RP-HPLC method for simultaneously estimating minoxidil and aminexil in pharmaceutical formulations with good accuracy and specificity.

This study developed and validated a reliable RP-HPLC method for accurately quantifying dutasteride in pharmaceutical formulations and bulk pharmaceuticals using a Shiseido C18 analytical column, demonstrating precision, accuracy, and sensitivity across a concentration range of 10 to 22 ppm.

This study established an accurate, reliable, and sensitive HPLC method to detect the illegal addition of minoxidil in herbal hair growth products.

Large prostate patients more likely to have hair loss.

In this review, the authors examine the causes, risk factors, and management strategies for chemotherapy-induced hair loss, highlighting its psychological impact and underscoring the role of healthcare providers, especially nurses, in supporting patients through this distressing side effect.